Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC weekly Stock Chart
AZN [NASD]
AstraZeneca PLC
Index- P/E55.32 EPS (ttm)0.95 Insider Own0.50% Shs Outstand2.62B Perf Week-2.63%
Market Cap136.07B Forward P/E17.64 EPS next Y2.98 Insider Trans0.00% Shs Float2.60B Perf Month3.20%
Income2.50B PEG2.88 EPS next Q0.64 Inst Own16.90% Short Float0.24% Perf Quarter-5.53%
Sales25.87B P/S5.26 EPS this Y-39.70% Inst Trans-4.55% Short Ratio1.31 Perf Half Y-4.62%
Book/sh4.65 P/B11.31 EPS next Y13.08% ROA4.10% Target Price60.63 Perf Year7.87%
Cash/sh3.27 P/C16.11 EPS next 5Y19.20% ROE20.70% 52W Range36.15 - 64.94 Perf YTD5.52%
Dividend1.40 P/FCF- EPS past 5Y1.00% ROI8.30% 52W High-18.99% Beta0.58
Dividend %2.66% Quick Ratio0.80 Sales past 5Y-1.70% Gross Margin80.10% 52W Low45.53% ATR1.37
Employees70600 Current Ratio1.00 Sales Q/Q2.70% Oper. Margin16.40% RSI (14)42.73 Volatility1.90% 1.76%
OptionableYes Debt/Eq1.83 EPS Q/Q116.60% Profit Margin9.70% Rel Volume3.07 Prev Close52.60
ShortableYes LT Debt/Eq1.54 EarningsNov 05 BMO Payout147.40% Avg Volume4.82M Price52.61
Recom1.60 SMA20-3.25% SMA50-2.78% SMA2000.81% Volume14,775,977 Change0.02%
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Nov-29-20 05:02PM  
09:06AM  
06:25AM  
Nov-28-20 07:45PM  
04:28PM  
12:06PM  
09:10AM  
08:53AM  
07:30AM  
07:05AM  
02:41AM  
Nov-27-20 05:30PM  
04:41PM  
01:46PM  
01:30PM  
01:27PM  
01:10PM  
12:27PM  
12:13PM  
11:41AM  
11:01AM  
10:30AM  
10:26AM  
10:25AM  
10:05AM  
10:03AM  
09:57AM  
09:00AM  
08:52AM  
08:47AM  
08:47AM  
08:39AM  
08:00AM  
07:48AM  
06:46AM  
04:58AM  
04:03AM  
03:04AM  
02:16AM  
Nov-26-20 07:01PM  
03:31PM  
02:11PM  
12:53PM  
12:26PM  
11:58AM  
11:48AM  
11:14AM  
06:30AM  
04:50AM  
03:55AM  
01:51AM  
12:14AM  
Nov-25-20 04:55PM  
04:28PM  
03:36PM  
12:48PM  
12:01PM  
11:43AM  
10:16AM  
07:43AM  
07:00AM  
06:55AM  
06:00AM  
Nov-24-20 05:12PM  
02:39PM  
01:39PM  
01:36PM  
01:30PM  
01:20PM  
12:10PM  
12:05PM  
11:45AM  
11:27AM  
10:53AM  
10:32AM  
10:30AM  
09:21AM  
08:12AM  
08:10AM  
07:57AM  
07:50AM  
07:40AM  
06:57AM  
06:37AM  
04:52AM  
04:32AM  
03:43AM  
02:00AM  
01:03AM  
12:44AM  
Nov-23-20 08:10PM  
07:25PM  
06:05PM  
06:00PM  
05:42PM  
05:40PM  
05:24PM  
05:00PM  
04:53PM  
04:42PM  
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.